As small molecules and antibodies inhibiting the activity of tyrosine kinases are effective tools in cancer treatment [38], regulators of tyrosine kinase activity like the tyrosine phosphatase PTPRE hold the potential of new future RB therapy targets. The gene discussed is PTPRE; the disease is cancer.